Howard Marks
Oaktree Capital Management
Howard Marks BELLEVUE LIFE SCIENCES-WRNT stake
total: 853
Oaktree Capital Management BLACW trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2023 Q1
- Held for:
- 1 quarter
- Latest activity:
- 2023 Q2
According to 2026 Q2 report, Howard Marks doesn't hold any BELLEVUE LIFE SCIENCES-WRNT (BLACW) shares. To date, the estimated cost basis is nearly $0.07 for "buy" trades and estimated average "sell" price is $0.07. Oaktree Capital Management first purchased BLACW in 2023 Q1, initially acquiring 175,000 shares. Since the initial investment in BELLEVUE LIFE SCIENCES-WRNT (BLACW), Oaktree Capital Management has made 1 more transaction.
When did Howard Marks sell BELLEVUE LIFE SCIENCES-WRNT (BLACW)?
Howard Marks sold off the entire BELLEVUE LIFE SCIENCES-WRNT (BLACW) position in 2023 Q2.
When did Howard Marks buy BELLEVUE LIFE SCIENCES-WRNT (BLACW)?
Howard Marks first invested in BELLEVUE LIFE SCIENCES-WRNT (BLACW) in 2023 Q1 at the reported quarter-end price of $0.07 per share.
What's the cost basis of Oaktree Capital Management's BLACW stake?
The estimated cost basis for BELLEVUE LIFE SCIENCES-WRNT (BLACW) stake is around $0.07 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $0.07
- Weighted AVG sell price:
- $0.07
Howard Marks's historical trades in BELLEVUE LIFE SCIENCES-WRNT
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2023 Q2
|
0.00%
|
0
|
$0.07
|
|
-100% (-175,000)
|
-0%
|
|
2023 Q1
|
0.00%
|
175,000
|
$0.07
|
$12,250
|
new
|
+0%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.